Form D · Pharmaceuticals

Valanbio Therapeutics, Inc.

Raleigh, NC · CIK 0001771623

Offering snapshot reported Jan 14, 2020 · SEC filing

Reported sold
$421K
Offering amount: $600K
Investors reported
5
Form D · investor count
Minimum accepted
$7K
Reported outside-investor minimum
First sale
Aug 27, 2018
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$211K$421KSep 6, 2019: $121,000.00Sep 6, 2019Jan 14, 2020: $421,000.00Jan 14, 2020

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$121,000 → $421,000
  • Reported investors4 → 5

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 14, 2020Amendment$421,000$300,000vs Sep 6, 20195SEC filing
Sep 6, 2019Initial$121,000No comparison4SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-348130

Source: Form D, filed Jan 14, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Clayton Duncan Director, Executive
Sam Hopkins Director
Moise A. Khayrallah Director, Executive
Eric J. Toone Director
Pei Zhou Director, Executive

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1120 Longstone Way
Raleigh, NC, 27614